These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 116611)

  • 1. [Average steady-state plasma levels with slow release quinidine preparations].
    Normand JP; Roux A; Bardet J; Kahn JC; Maspoli JJ; Jarreau FX; Sansarricq M; Flouvat B; Bourdarias JP
    Arch Mal Coeur Vaiss; 1979 Sep; 72(9):1006-13. PubMed ID: 116611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioavailability of two manufacturers' sustained-release quinidine gluconate tablets at steady state.
    Zinny MA; Taggart WV
    Clin Ther; 1984; 7(1):22-7. PubMed ID: 6518461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioavailability of quinidine in slow-release form. A comparison between two preparations containing quinidine bisulphate as the active constituent.
    Regårdh CG; Johnsson G; Lundborg P; Perrson BA
    Arzneimittelforschung; 1977; 27(9):1716-8. PubMed ID: 21671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steady-state bioavailability of two sustained-release quinidine preparations: quinidine gluconate versus quinidine sulfate.
    Taggart WV; Holyoak W
    Clin Ther; 1983; 5(4):357-64. PubMed ID: 6871920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma level studies of quinidine retard, their significance for dosage and onset of effect].
    Guckenbiehl W; Just H; Olbermann M; Lang KF
    Med Klin; 1976 Apr; 71(14):586-92. PubMed ID: 57566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between quinidine plasma level and clinical effect for a new quinidine retard-formulation (author's transl)].
    Gaul G; Aldor E
    Arzneimittelforschung; 1981; 31(9):1486-8. PubMed ID: 7197961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid elimination of quinidine in pediatric patients.
    Szefler SJ; Pieroni DR; Gingell RL; Shen DD
    Pediatrics; 1982 Sep; 70(3):370-5. PubMed ID: 7110810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relative bioavailability and influence of a quinidine retard-formulation on blood-pressure and ECG in healthy volunteers (author's transl)].
    Knapp W; Lechleitner P
    Arzneimittelforschung; 1981; 31(9):1482-6. PubMed ID: 7197960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability of a slow-release theophylline capsule given twice daily to preschool children with chronic asthma: comparison with liquid theophylline.
    Sallent J; Hill M; Stecenko A; McKenzie M; Hendeles L
    Pediatrics; 1988 Jan; 81(1):116-20. PubMed ID: 3336577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An experimental model for the rational treatment of arrhythmias: a clinical study with quinidine].
    Pelosi G; Duca G; Bareggi SR; Pirola R; Hadëri B
    G Ital Cardiol; 1993 Aug; 23(8):777-86. PubMed ID: 8119501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative quinidine plasma profiles at steady state of two controlled-release products and quinidine sulfate in solution.
    Wright GJ; Melikian AP; Pitts JE; Crowe JT; Morley EM
    Biopharm Drug Dispos; 1987; 8(2):159-72. PubMed ID: 3593896
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of sustained-release quinidines given twice daily to patients with ventricular ectopy.
    Lehmann CR; Boran KJ; Kruyer WB; Van Reet RE; Scoville GS; Pierson WP; Melikian AP; Crowe JT; Wright GJ
    J Clin Pharmacol; 1986; 26(8):598-604. PubMed ID: 3793950
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative bioavailability of sustained-release and conventional tablets of hydroxyethyltheophylline in man.
    Sharma PL; Sharma RM
    Int J Clin Pharmacol Biopharm; 1979 Sep; 17(9):394-6. PubMed ID: 583044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pharmacokinetics of theophylline. Repeated single evening administration of Pulmo-Timelets slow-release capsules in comparison with theophylline slow-release tablets].
    Heusinger JH; Breuel HP; Behrendt WA; Wolfstädter HD
    Fortschr Med; 1989 Nov; 107(32):692-6. PubMed ID: 2689314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steady-state serum quinidine concentration: role in prophylactic therapy following acute myocardial infarction.
    Halkin H; Vered Z; Millman P; Rabinowitz B; Neufeld HN
    Isr J Med Sci; 1979 Jul; 15(7):583-7. PubMed ID: 478822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Time course of oxipurinol levels in plasma following single dose and chronic administration of allopurinol in different pharmaceutical preparations (author's transl)].
    Walter-Sack I; Gröbner W; Zöllner N
    Arzneimittelforschung; 1979; 29(5):839-42. PubMed ID: 582985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinidine dosage, with special reference to an oral loading dose schedule.
    Collste P; Nordlander R
    Br J Clin Pharmacol; 1979 Mar; 7(3):293-7. PubMed ID: 427006
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of quinidine in two sustained-release preparations.
    Garty M; Rachmel A; Ilfeld D; Sinai Y; Paz R
    Isr J Med Sci; 1992 Jun; 28(6):357-61. PubMed ID: 1607272
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic analysis of intravenously and orally administered quinidine in cows.
    McGuirk SM; Muir WW; Sams RA
    Am J Vet Res; 1981 Sep; 42(9):1482-7. PubMed ID: 7325456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparative study of plasma levels of 2 delayed-action theophyllines: Theostat 200 and Theodur 200, after a single evening dose].
    Philip-Joet F; Bruguerolle B; Lagier F; Arnaud A
    Rev Pneumol Clin; 1986; 42(6):279-83. PubMed ID: 3563255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.